Spyre Therapeutics
SYRE
26 hedge funds and large institutions have $24.4M invested in Spyre Therapeutics in 2016 Q4 according to their latest regulatory filings, with 4 funds opening new positions, 7 increasing their positions, 4 reducing their positions, and 6 closing their positions.
75% more repeat investments, than reductions
Existing positions increased: 7 | Existing positions reduced: 4
1.67% more ownership
Funds ownership: 0% → 1.67% (+1.7%)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
7% less funds holding
Funds holding: 28 → 26 (-2)
33% less first-time investments, than exits
New positions opened: 4 | Existing positions closed: 6
36% less capital invested
Capital invested by funds: $38M → $24.4M (-$13.6M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Vanguard Group
Malvern,
Pennsylvania
|
+$235K |
| 2 |
SCM
Sio Capital Management
New York
|
+$199K |
| 3 |
Jennison Associates
New York
|
+$121K |
| 4 |
Wells Fargo
San Francisco,
California
|
+$84.4K |
| 5 |
SIM
Spark Investment Management
New York
|
+$70K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
RCM
RA Capital Management
Boston,
Massachusetts
|
-$2.15M |
| 2 |
GTC
Ghost Tree Capital
New York
|
-$321K |
| 3 |
Millennium Management
New York
|
-$230K |
| 4 |
Goldman Sachs
New York
|
-$132K |
| 5 |
UBS Group
Zurich,
Switzerland
|
-$96.7K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
RCM
26
RA Capital Management
Boston,
Massachusetts
| – | -$2.15M | -13,445 | Closed |
|
|
GTC
27
Ghost Tree Capital
New York
| – | -$321K | -2,000 | Closed |
|
|
28
Millennium Management
New York
| – | -$230K | -1,438 | Closed |
|
|
TG
29
TLP Group
Evanston,
Illinois
| – | -$76K | -477 | Closed |
|
|
CS
30
Credit Suisse
Zurich,
Switzerland
| – | -$64K | -400 | Closed |
|
31
Bank of America
Charlotte,
North Carolina
| – | -$3K | -18 | Closed |
|
32
Bank of Montreal
Toronto,
Ontario, Canada
| – | +$146 | +1 | New |
|
SYRE Hedge Fund Activity: Q4 2016 in Review
26 of the 4,000 institutional investors tracked by Wall St. Rank reported a position in Spyre Therapeutics (SYRE) for Q4 2016, worth a combined $24.4M — down 36% from $38M a quarter earlier.
Sellers outnumbered buyers: 6 funds closed out of SYRE and 4 opened new positions — a net loss of 2 holders — while 4 trimmed existing stakes and 7 added.
The largest buyer was Vanguard Group, adding an estimated $235K. The largest seller was RA Capital Management, exiting entirely with an estimated $2.15M sold.
- 26 institutional investors held Spyre Therapeutics (SYRE) as of Q4 2016, down from 28 in Q3 2016.
- Funds reported $24.4M of Spyre Therapeutics stock for Q4 2016, down 36% quarter-over-quarter.
- 4 funds opened new Spyre Therapeutics positions in Q4 2016 and 6 closed out, a net change of -2 holders.
- The largest Spyre Therapeutics buyer in Q4 2016 was Vanguard Group, an estimated $235K added.
- The largest Spyre Therapeutics seller in Q4 2016 was RA Capital Management, an estimated $2.15M sold.
Based on aggregated 13F filings for Q4 2016.